WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Momenta Pharmaceuticals
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Labiotech.eu | January 27, 2020
Most treatments for inflammatory diseases have single targets, such as an inflammation-promoting cytokine or a protein complex called an inflammasome. Quench Bio is taking aim at a family of proteins involved in inflammatory cell death—and it’s picked up $50 million to do so. Seeded by Atlas Venture and Arix Bioscience and incubated at Atlas since its inception in 2018, Quench's first target is gasdermin D, the best understood member of the gasdermin family of proteins. With its ...
Industrial Impact
IFF | February 17, 2022
IFF announced that it has entered into an agreement to acquire Health Wright Products, LLC (HWP), a leader in formulation and capsule manufacturing for the dietary supplement industry. Founded in 1995, HWP is located in Clackamas, Oregon, USA, and is a privately-owned and long-time business partner of IFF’s Health & Biosciences probiotics business. HWP is a global leader in the consumer Health and Nutrition industries, providing the highest-quality nutritional supplement...
Medical, Industry Outlook
Businesswire | August 11, 2023
TriSalus Life Sciences® Inc. an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced the completion of its previously announced merger with MedTech Acquisition Corporation (Nasdaq: MTAC) (MedTech). TriSalus’ common stock and warrants are expected to commence trading on the Nasdaq Global Market under the ticker symbols “TLSI” and “TLSIW,” respectiv...
PharmaMar | April 28, 2020
PharmaMar (MSE: PHM) has announced the start of the APLICOV-PC clinical trial with Aplidin® (plitidepsin), for the treatment of patients with COVID-19, which has been authorized by the Spanish Medicines and Healthcare Products Agency (AEMPS). This is a multicenter, randomized, parallel, open-label study to evaluate the safety profile and efficacy of three doses of plitidepsin in patients with COVID-19 requiring hospital admission. Three hospitals from Madrid (Spain) will participate in the s...
Cell and Gene Therapy
Video
Whitepaper
Cell and Gene Therapy, Medical
Medical
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE